RECRUITINGINTERVENTIONAL

Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine

Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine Using the PedMIDAS Measuring Tool.

About This Trial

Flunarizine and propranolol have demonstrated efficacy in reducing migraine frequency across age groups, though evidence in pediatric populations remains limited and inconsistent. Therefore, the current study has been planned to evaluate and compare the effectiveness of flunarizine and propranolol in reducing migraine frequency in children aged 8-15 using the Pediatric Migraine Disability Assessment Scale (PedMIDAS) score.

Who May Be Eligible (Plain English)

Who May Qualify: - Children of any gender - Aged 8-15 years - Diagnosed with migraine (with/without aura) per International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria - A history of ≥4 migraine attacks/month for the preceding 3 months - With a PedMIDAS score ≥11 (moderate-to-severe impact) Who Should NOT Join This Trial: - Children with secondary headache disorders (e.g., due to infections, trauma, structural brain lesions) - Known hypersensitivity or contraindications to flunarizine or propranolol - Presence of cardiovascular disorders (e.g., bradycardia, heart block, hypotension, asthma) - Non-compliance or inability to attend regular follow-ups - Participation in another clinical trial within the last 3 months Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Children of any gender * Aged 8-15 years * Diagnosed with migraine (with/without aura) per International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria * A history of ≥4 migraine attacks/month for the preceding 3 months * With a PedMIDAS score ≥11 (moderate-to-severe impact) Exclusion Criteria: * Children with secondary headache disorders (e.g., due to infections, trauma, structural brain lesions) * Known hypersensitivity or contraindications to flunarizine or propranolol * Presence of cardiovascular disorders (e.g., bradycardia, heart block, hypotension, asthma) * Non-compliance or inability to attend regular follow-ups * Participation in another clinical trial within the last 3 months

Treatments Being Tested

DRUG

Flunarizine

Patients will be receiving flunarizine beginning with 5 mg at bedtime and increasing it to 10 mg at bedtime after 1 month, over a 3-month treatment period.

DRUG

Propranolol

Patient will be given propranolol beginning with 10 mg/24 hours and increase at the rate of 10 mg/week to the maximum of 60 mg/24 hour, over a 3-month treatment period.

Locations (1)

The Children's Hospital Lahore

Lahore, Punjab Province, Pakistan